---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-25-000138"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:12:43.050758+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio Q3 product revenue up 434% YoY to $31.8M; net loss narrows to $67.3M

## Summary
- Product revenue $31.8M in Q3 2025 vs $6.0M in Q3 2024; YTD sales $74.7M (+434%).
- ANKTIVA unit volumes up 467% YTD 2025 vs FY2024; net loss attributable to common $67.3M (vs $85.7M).
- Cash and securities $257.8M at Sep 30, 2025, up from $153.7M at Jun 30, 2025.
- Early glioblastoma combo study: 100% disease control (2 near-complete responses, 3 stable).
- Phase 3 NSCLC trial (ResQ201A) initiated; ANKTIVA named preferred drug by ~80M-life organization.

## SEC filing metadata
- accession: 0001326110-25-000138
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611025000138/0001326110-25-000138-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611025000138/ibrx-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-25-000138
- JSON: https://secwatch.observer/filing/0001326110-25-000138.json
- Plain text: https://secwatch.observer/filing/0001326110-25-000138.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.